Cancer Treatment News and Research

RSS

N-of-One develops unique knowledge integration platform for oncologists

N-of-One, Inc., provider of Diagnostic Strategy Roadmaps and Treatment Strategy Roadmaps for personalized cancer care, announced today that the company has developed a unique knowledge integration platform to enable care providers and patients to make informed decisions about diagnostic and treatment strategy.

1 Jun 2012

Researchers devise strategy to directly activate natural ‘death’ protein

Researchers at Dana-Farber/Children's Hospital Cancer Center have devised a strategy to directly activate a natural "death" protein, triggering the self-destruction of cells. They say the development could represent a new paradigm for designing cancer drugs.

1 Jun 2012

GE to provide attendees with overview of new oncology solutions at ASCO annual meeting

GE Healthcare, is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.

31 May 2012

Surprising life-quality benefit from early prostate cancer treatment

Treatment of early-stage prostate cancer may also improve quality of life if patients have previously suffered from obstructive urinary symptoms before undergoing treatment, shows US research.

30 May 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Blocking Skp2 protein might inhibit glycolysis and treat breast cancer

HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in the May 25 issue of Cell.

28 May 2012

NIH Consortium selects UBM among 11 CoEPEs

With more Americans than ever living with chronic pain, the National Institutes of Health (NIH) Pain Consortium wants the University of Maryland, Baltimore (UMB) and 10 other health professional schools to teach the next generation of health care providers to be better equipped to manage and treat such patients.

25 May 2012

Scars, disfigurement and hair loss from childhood cancer can affect adult quality of life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced quality of life in adulthood, according to a new study led by a Northwestern Medicine advanced practice nurse, Karen Kinahan, and based on data from the Childhood Cancer Survivor Study.

25 May 2012

Cancer diagnosis may increase risk of death in men with mental illness

Men suffering from psychiatric problems when diagnosed with cancer are more likely to die from the disease, according to a new study published today in the British Journal of Cancer.

24 May 2012

Federal task force recommends dropping routine prostate cancer test

The U.S. Preventive Services Task Force finds scant evidence that the PSA blood test saves lives and instead says unneeded treatment leads to serious problems, including impotence and incontinence.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

CTCA wins 2012 HealthGrades Outstanding Patient Experience Award

Cancer Treatment Centers of America (CTCA) at Midwestern Regional Medical Center (Midwestern) proudly announced today that it has received the 2012 HealthGrades Outstanding Patient Experience Award -- one of only four recipients in all of Chicagoland, one of 13 in Illinois, and one of 332 nationwide to receive the prestigious award. This is the third consecutive year that CTCA at Midwestern has been recognized with the honor.

22 May 2012

TTFields therapy vs. chemotherapy in patients with recurrent glioblastoma

Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer.

21 May 2012

Study shows how a drug-lead compound suppresses tumour formation

A team of scientists from the National University of Singapore's (NUS) Department of Biological Sciences and Mechanobiology Institute have discovered how a drug-led compound - a compound that is undergoing preclinical trials as a potential drug - can deprive cancer cells of energy and stop them from growing into a tumour. This drug-led compound is named BPTES.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Study identifies biomarkers that predict patients' response to certain colon cancer drugs

The Stem Cells and Cancer Research Group headed by Dr H-ctor G. Palmer at the Vall d'Hebr-n Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Mu-oz-s laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cient-ficas.

21 May 2012

Childhood cancer research computing cluster to support precision medicine clinical trial

The childhood cancer research computing cluster created and donated by Dell for the Translational Genomics Research Institute (TGen) is ready to support the world's first precision medicine clinical trial for pediatric cancer.

19 May 2012

Scientists map how XIAP protein activates vital component of immune defence system

Defects in the gene that encodes the XIAP protein result in a serious immune malfunction. Scientists used biochemical analyses to map the protein's ability to activate vital components of the immune system. Their results have recently been published in Molecular Cell, a journal of international scientific repute.

18 May 2012

MSRG researchers develop ColoREctal Wellbeing study

Researchers from the Macmillan Survivorship Research Group (MSRG), at the University of Southampton, have developed the first study of its kind looking at the experiences and needs of people after primary treatment of colorectal cancer.

18 May 2012